Viewing StudyNCT04967248



Ignite Creation Date: 2024-05-06 @ 4:22 PM
Last Modification Date: 2024-10-26 @ 2:09 PM
Study NCT ID: NCT04967248
Status: RECRUITING
Last Update Posted: 2023-09-21
First Post: 2021-07-08

Brief Title: A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women and Men With HRHER2- Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation After Disease Progression Following Endocrine Therapy as Monotherapy in the Real-world Setting
Sponsor: Novartis Pharmaceuticals
Organization: Novartis

Conditions & Keywords Data

Conditions:
Name
Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
Keywords:
Name View
PASS View
Breast Cancer View
non-interventional study View
NIS View
alpelisib View
fulvestrant View